Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CISPLATIN
Ebewe Pharma Ges.m.b.H Nfg. KG
CISPLATIN
0.5 Micromol
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
SANDOZ Business use only Page 1 of 10 1.3.1 spc-label-pl - common-pl – 3,132 (NL/H/0118/001-002-003/IB/043) 20130411 Cisplatin, Concentrate for solution for infusion 722-0340.00 1 PACKAGE LEAFLET: INFORMATION FOR THE USER CISPLATIN ‘EBEWE’ 0.5 MG/ML, CONCENTRATE FOR SOLUTION FOR INFUSION cisplatin _ _ IN THIS LEAFLET: 1. What Cisplatin “Ebewe” 0.5 mg/ml is and what it is used for 2. Before you are given Cisplatin “Ebewe” 0.5 mg/ml 3. How you are given Cisplatin “Ebewe” 0.5 mg/ml 4. Possible side effects 5. How to store Cisplatin “Ebewe” 0.5 mg/ml 6. Further information 1. WHAT CISPLATIN IS AND WHAT IT IS USED FOR Cisplatin forms part of a group of medicines called cytostatics, which are used in the treatment of cancer. Cisplatin can be used alone but more commonly Cisplatin is used in combination with other cytostatics. WHAT IS IT USED FOR? Cisplatin can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary, head and neck epithelial tumour (tumour affecting the outer tissue layer of the skin), tumour in the lung). Your doctor will be able to provide you with more information. _ _ 2. BEFORE YOU TAKE CISPLATIN DO NOT TAKE CISPLATIN IF: you are allergic (hypersensitive) to cisplatin or to any of the other ingredients of Cisplatin you are allergic (hypersensitive) to any other medicine that contains platin you have kidney problems (renal dysfunction) you suffer from dehydration READ ALL OF THIS_ _LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or your pharmacist. - This medicine Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cisplatin ‘Ebewe’ 0.5 mg/ml – Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 0.5 mg cisplatin. 1 vial of 20 ml concentrate for solution for infusion contains 10 mg cisplatin. 1 vial of 50 ml concentrate for solution for infusion contains 25 mg cisplatin. 1 vial of 100 ml concentrate for solution for infusion contains 50 mg cisplatin. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion The concentrate is a clear and colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours: testicular carcinoma (palliative and curative poly-chemotherapy) and ovary carcinoma (stages III and IV), and head and neck squamous-cell epithelioma (palliative therapy). In the treatment of small cell lung carcinoma. In the treatment of advanced non-small cell lung carcinoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cisplatin "Ebewe" 0.5mg/ml concentrate for solution for infusion is to be diluted before use (see section 6.6.). The diluted solution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided (see section 6.2.). ADULTS AND CHILDREN: The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of a combination chemotherapy. The dosage directions are applicable for both adults and children. For recommendations on the dosage applicable, based on the di Read the complete document